A phase I, randomised, double-blind, placebo-controlled, multi-centre, ascending-dose trial to evaluate the safety, tolerability and immunogenicity of Vaccine FP-02.2 in HBeAg-negative hepatitis B patients as an add-on treatment to entecavir or tenofovir.

1st May 2016 - ongoing

Status: Active

Specialism: Liver.

Team: Dr Stephen Ryder.